Fujifilm Diosynth Biotechnologies Expands Cell Culture Manufacturing Capacity
![](/46/pdcnewsitem/03/35/70/RZ0wI6lv0K31OVU.png)
Fujifilm Diosynth Biotechnologies has announced continued expansion of its cell culture manufacturing capabilities with the addition of two 2000-L single-use bioreactors. One each of these is being installed at the company’s sites in Research Triangle Park (RTP), NC, USA and Billingham, UK.
The new reactors will complement the range of vessels at both sites, adding further flexibility for customer requirements. Each site currently operates 1000-L single-use bioreactors with 250–1000-L operating volumes, with an additional 200-L single-use bioreactor in the UK, and a 2000-L stainless steel train in RTP, which has been in place for a number of years manufacturing a range of products.
“The addition of these two new bioreactors will meet the demand we are seeing for a 2000-L platform, and offer a cost-effective, low-risk route to market through ‘scaling-out’ from early phase to commercial manufacture” says Mr Steve Bagshaw, CEO, Fujifilm Diosynth Biotechnologies. He adds: “Being similar to our existing bioreactors means they will fit seamlessly into our facilities. Having identical single-use operations on both sides of the Atlantic offers our customers flexibility and easy access to global markets. Combined with the expertise of our process development scientists to produce high-titer cell lines, our focus on single-use bioreactor technology for cell culture processes is world class.”
The company has over 15 years’ cell culture manufacturing experience with significant single-use facility expansions in the last 3 years at both sites. The facilities have been inspected by key regulatory authorities and utilise both traditional platforms as well as the latest single-use technologies. The new 2000-L bioreactors are expected to be operational by November 2014 in the US and in the UK in January 2015.
Mr Bagshaw concluded: “With these expansions, Fujifilm Diosynth Biotechnologies is able to deliver a significantly enhanced, full life cycle ‘Gene to GMP’ service for our customers".
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance